Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry

Arthritis and Rheumatism

Volumn 62, Issue 8, 2010, Pages 2458-2466

  Terrier, Benjamin ^a   Amoura, Zahir ^b   Ravaud, Philippe ^c   Hachulla, Eric ^d   Jouenne, Romain ^a   Combe, Bernard ^e   Bonnet, Christine ^f   Cacoub, Patrice ^b   Cantagrel, Alain ^g   De Bandt, Michel ^h   Fain, Olivier ⁱ   Fautrel, Bruno ^b   Gaudin, Philippe ^j   Godeau, Bertrand ^k   Harlé, Jean Robert ^l   Hot, Arnaud ^m   Kahn, Jean Emmanuel ⁿ   Lambotte, Olivier ^a   Larroche, Claire ^o   Léone, Jean ^p   Meyer, Olivier ^c   Pallot Prades, Béatrice ^q   Pertuiset, Edouard ^r   Quartier, Pierre ^s   Schaerverbeke, Thierry ^t   Sibilia, Jean ^u   Somogyi, Alexandre ^v   Soubrier, Martin ^w   Vignon, Eric ^m   Bader Meunier, Brigitte ^s   Mariette, Xavier ^a   Gottenberg, Jacques Eric ^u   more..

^a BICÊTRE HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e LAPEYRONIE HOSPITAL   (France)

^f DUPUYTREN UNIVERSITY HOSPITAL   (France)

^g CHU PURPAN   (France)

^h Centre Hospitalier Robert Ballanger CHRB   (France)

ⁱ HÔPITAL JEAN VERDIER   (France)

^j Hopital Sud CHU de Grenoble   (France)

^k HENRI MONDOR HOSPITAL   (France)

^l HÔPITAL DE LA CONCEPTION   (France)

^m EDOUARD HERRIOT HOSPITAL   (France)

ⁿ FOCH HOSPITAL   (France)

^o AVICENNE HOSPITAL   (France)

^p SERVICE DE DERMATOLOGIE   (France)

^q SERVICE DE NEUROLOGIE   (France)

^r CENTRE HOSPITALIER RENÉ DUBOS   (France)

^s HÔPITAL NECKER ENFANTS MALADES   (France)

^t HÔPITAL PELLEGRIN   (France)

^u HÔPITAL DE HAUTEPIERRE   (France)

^v CENTRE HOSPITALIER INTERCOMMUNAL   (France)

^w SERVICE DE RHUMATOLOGIE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ESTROGEN; HEMOGLOBIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ACUTE TOXICITY; ADOLESCENT; ADULT; AGED; ALOPECIA; ANAPHYLACTIC SHOCK; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM; CHILD; CHOLANGITIS; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; DELAYED HYPERSENSITIVITY; DISCOID LUPUS ERYTHEMATOSUS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; ESTROGENS IN LUPUS ERYTHEMATOSUS NATIONAL ASSESSMENT; FEMALE; GLOMERULUS FILTRATION RATE; HEMATOLOGY; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPOTENSION; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; JOINT; JOINT SWELLING; KIDNEY; LUNG; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYOCARDITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RASH; RELAPSE; SCHOOL CHILD; SCORING SYSTEM; SEPTICEMIA; SERUM SICKNESS; SKIN; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX; THROMBOEMBOLISM; TREATMENT RESPONSE; ULCER; VASCULITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANAPHYLAXIS; ANTIBODIES, MONOCLONAL; CHILD; FEMALE; FRANCE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; REGISTRIES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 77955379986     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27541     Document Type: Article

References (19)

1. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007;369:587-96.
2. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39.
3. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003;82:299-308. (Pubitemid 37229465)
4. Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009;61:482-7.
5. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009;18:767-76.
6. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-toseverely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.
7. Furie R, Looney RJ, Rovin B, Latinis KM, Appel G, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR Study [abstract]. Arthritis Rheum 2009;60 Suppl:S429.
8. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44.
9. Dixon WG, Watson K, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, et al, on behalf of the British Society for Rheumatology Biologics Register. Rates of serious infection, including sitespecific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76.
10. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
11. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
12. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
13. Melander C, Sallee M, Trolliet P, Candon S, Belenfant X, Daugas E, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009;4:579-87.
14. Bussone G, Ribeiro E, Dechartres A, Viallard JF, Bonnotte B, Fain O, et al. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases. Am J Hematol 2009;84:153-7.
15. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-93.
16. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al, on behalf of the International Society of Nephrology and Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-50.
17. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 2007;66:351-7. (Pubitemid 46579637)
18. Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al, and the RAVE-ITN Research Group. Rituximab versus cyclophosphamide for induction of remission in ANCA-associated vasculitis: a randomized controlled trial (RAVE) [abstract]. Arthritis Rheum 2009;60 Suppl:S204.
19. Ramos-Casals M, Diaz-Lagares C, Khamashta MA. Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al [letter]. Arthritis Rheum 2009;61:1281-2.